4.7 Article

APOE ε4 carriers may undergo synaptic damage conferring risk of Alzheimer's disease

Journal

ALZHEIMERS & DEMENTIA
Volume 12, Issue 11, Pages 1159-1166

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jalz.2016.05.003

Keywords

Synaptic function; Neurogranin; APOE epsilon 4; Alzheimer's disease; APOE; Mild cognitive impairment

Funding

  1. Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health) [U01 AG024904]
  2. DOD ADNI (Department of Defense) [W81XWH-12-2-0012]
  3. National Institute on Aging
  4. National Institute of Biomedical Imaging and Bioengineering
  5. Canadian Institutes of Health Research
  6. AbbVie
  7. Alzheimer's Association
  8. Alzheimer's Drug Discovery Foundation
  9. Araclon Biotech
  10. BioClinica, Inc.
  11. Biogen
  12. Bristol-Myers Squibb Company
  13. CereSpir, Inc.
  14. Eisai
  15. Elan Pharmaceuticals, Inc.
  16. Eli Lilly and Company
  17. EuroImmun
  18. F. Hoffmann-La Roche Ltd. and its affiliated company Genentech, Inc.
  19. Fujirebio
  20. GE Healthcare
  21. IXICO Ltd.
  22. Janssen Alzheimer Immunotherapy Research & Development, LLC
  23. Johnson & Johnson Pharmaceutical Research & Development LLC
  24. Lumosity
  25. Lundbeck
  26. Merck Co., Inc.
  27. Meso Scale Diagnostics, LLC
  28. NeuroRx Research
  29. Neurotrack Technologies
  30. Novartis Pharmaceuticals Corporation
  31. Pfizer Inc.
  32. Piramal Imaging
  33. Servier
  34. Takeda Pharmaceutical Company
  35. Transition Therapeutics

Ask authors/readers for more resources

Introduction: Pathogenesis of Alzheimer's disease (AD) in apolipoprotein E epsilon 4 (APOE epsilon 4) carriers remains unclear. We hypothesize that APOE isoforms have differential effects on synaptic function. Methods: We compared levels of CSF neurogranin (Ng) between APOE epsilon 4 carriers and noncarriers in 399 subjects with normal cognition, mild cognitive impairment (MCI), and AD. We examined associations between Ng levels and age, education, gender, CSF-A beta 42, and tau protein. Results: Neurogranin levels were significantly higher in APOE epsilon 4 carriers compared to APOE epsilon 4 noncarriers with MCI. Levels of Ng between the APOE epsilon 4 carriers and APOE 64 noncarriers with AD did not differ. Ng levels were correlated with MMSE and levels of tau and A beta 42. Discussion: Significantly higher CSF Ng levels in APOE epsilon 4 carriers with MCI may reflect synaptic injury underlying early cognitive impairment. Neurogranin may be an early biomarker of AD and important for disease diagnosis and timing of intervention in APOE epsilon 4 carriers. (C) 2016 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available